系统性红斑狼疮患者中抗Ro60抗体伴或不伴抗Ro52抗体的意义
研究纳入409例符合系统性红斑狼疮(SLE)分类标准的患者,按抗Ro状态分组,比较临床特征与疾病结局。47.2%为Ro阳性,Ro阳性与更高疾病活动度(HDAS OR 1.65,95%CI 1.10-2.48,P=0.015)、调整均值SLEDAI>4(OR 1.84,95%CI 1.18-2.88,P=0.007)及更频繁使用糖皮质激素(OR 1.87,95%CI 1.16-3.03,P=0.011)和免疫抑制剂(OR 2.0,95%CI 1.26-3.17,P=0.003)相关。
要点
- 409例SLE患者中47.2%为Ro阳性,Ro阳性与更高疾病活动度和治疗需求相关。
- Ro阳性患者更常出现HDAS(OR 1.65)、AMS>4(OR 1.84)及激素和免疫抑制剂使用增加。
- 多因素分析显示亚裔、严重复发、AMS、低补体血症、类风湿因子、蛋白尿、白细胞减少及口干眼干症状与Ro阳性显著相关。
主要发现
- 409例患者中47.2%为Ro阳性。
- Ro阳性患者以亚裔为主,dsDNA阳性及低补体血症更常见。
- Ro阳性患者HDAS可能性更高(OR 1.65,95%CI 1.10-2.48,P=0.015)。
- Ro阳性患者AMS>4可能性更高(OR 1.84,95%CI 1.18-2.88,P=0.007),且更频繁使用糖皮质激素(OR 1.87,95%CI 1.16-3.03,P=0.011)和免疫抑制剂(OR 2.0,95%CI 1.26-3.17,P=0.003)。
- 24.4%的Ro阳性患者出现口干眼干症状,高丙种球蛋白血症显著更常见;多因素分析证实亚裔、严重复发、AMS、低补体血症、类风湿因子、蛋白尿、白细胞减少及口干眼干症状与Ro阳性显著相关。
关键数值与推荐
- HDAS定义为曾达到SLEDAI2K≥10。
- Ro阳性定义为抗Ro60或抗Ro52任一阳性。
- Ro阳性患者HDAS的OR为1.65(95%CI 1.10-2.48,P=0.015)。
- Ro阳性患者AMS>4的OR为1.84(95%CI 1.18-2.88,P=0.007)。
临床怎么用
- 作者认为这些发现突显了抗Ro60/Ro52检测在SLE临床评估中的重要性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Anti-Ro60 and anti-Ro52 autoantibodies are frequently used as diagnostic biomarkers for Sjögren's disease, but their clinical significance in systemic lupus erythematosus (SLE) is not well characterized. METHODS: Patients fulfilling SLE classification criteria were studied according to their anti-Ro status. We defined Ro positivity (Ro+) as those who have either anti-Ro60 or anti-Ro52 positivity. Patient characteristics and disease outcomes, including High Disease Activity Status (HDAS) defined as an ever attainment of SLEDAI2K ≥10, adjusted mean SLEDAI (AMS), and time-adjusted mean clinical SLEDAI (excluding serologic activities) were compared using linear or logistic regressions. Furthermore, isolated or dual positivity of anti-Ro60 and anti-Ro52 were studied. RESULTS: Out of 409 patients, 47.2% were Ro+. Ro+ patients were predominantly Asian, had positive dsDNA and hypocomplementemia. They showed a higher likelihood of HDAS (OR 1.65, 95% CI 1.10-2.48, P = 0.015), AMS >4 (OR 1.84, 1.18-2.88, P = 0.007) and more frequent use of glucocorticoids (OR 1.87, 1.16-3.03, P = 0.011) and immunosuppressants (OR 2.0, 1.26-3.17, P = 0.003). Additionally, 24.4% of Ro+ patients experienced sicca symptoms, and hypergammaglobulinemia was significantly more common. Multivariate analysis confirmed that Asian ethnicity, severe flares, AMS, hypocomplementemia, rheumatoid factor, proteinuria, leucopenia and sicca symptoms were significantly linked to Ro positivity. CONCLUSION: Anti-Ro positivity is associated with higher disease activity and increased treatment needs. Ro positivity correlates with laboratory abnormalities such as hypocomplementemia and leucopenia. These findings highlight the importance of anti-Ro60/Ro52 testing in the clinical evaluation of SLE.
引用
- Liao K, Li N, Bonin J, et al. The implication of anti-Ro60 with or without anti-Ro52 antibody in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2025. PMID: 39141489. doi:10.1093/rheumatology/keae362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。